The Perfect-CR Implementation Study
Launched by SKANE UNIVERSITY HOSPITAL · May 25, 2023
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Administering secondary prevention via structured cardiac rehabilitation (CR) programs for patients who have suffered a myocardial infarction (MI) reduces mortality and morbidity and improves quality of life. Still, treatment goal achievement at patient-level and service delivery at center-level are sub-optimal and there is a large variation in program structure and delivery at center-level.
Using an open-label cluster-randomized effectiveness-implementation hybrid trial design, the primary objective of this study is to prospectively evaluate whether a) audit and feedback of CR processes a...
Gender
ALL
Eligibility criteria
- • Centre-level
- Inclusion Criteria:
- • Centres report to the SWEDEHEART registry
- Exclusion Criteria:
- • Unwillingness to participate in the study
- • Patient-level
- Inclusion Criteria:
- • Diagnosis of a type 1 MI registered in the SWEDEHEART registry
- • Age 18-79 years at discharge from hospital
- • Attended at least two follow-up visits at CR centres included in the study
- Exclusion Criteria:
- • None
About Skane University Hospital
Skåne University Hospital is a leading academic medical center located in Sweden, renowned for its commitment to advancing healthcare through innovative clinical research and trials. As a key player in the Nordic healthcare landscape, the hospital integrates cutting-edge medical practices with rigorous scientific inquiry, aiming to improve patient outcomes and foster advancements in medical knowledge. With a multidisciplinary approach, Skåne University Hospital collaborates with various stakeholders, including universities and research institutions, to conduct high-quality clinical trials that address critical health challenges and contribute to the development of new treatments and therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Malmö, , Sweden
Patients applied
Trial Officials
Margret Leosdottir
Principal Investigator
Skane University Hospital Malmö
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported